B+
Bull case
25%
Probability
Target price
$8.00
+72.0% vs current
KLRS
Kalaris TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$5.60
+20.4% vs current
B-
Bear case
25%
Probability
Target price
$2.70
-41.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-27
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+66.8
Score
AI commentary
Coverage is thin and the thesis remains a cautious monitoring-style biotech setup. Primary filings support a funded development path: cash runway into Q4 2027, rising R&D linked to site expansion and enrollment, and a 1H 2027 TH103 preliminary-data checkpoint. That is constructive for execution, but forward visibility is still dominated by one program, no meaningful analyst revision signal is available in the packet, and the peer set is only a loose micro-cap biotech context rather than a strong valuation comp set.
RankAlpha Sentiment Codex - 2026-05-27
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-12eventQ1 2026 10-Q confirms cash runway and ongoing clinic build-out [#10-Q-2026-05-12]Medium impact
The March 31, 2026 quarter update shows the company still funded for development work, with cash use tied to opening additional investigational sites and enrolling patients. That is constructive for execution, but it also confirms the program is still in the burn phase rather than a de-risked commercial story.
2027-06-30eventTH103 preliminary data in 1H 2027 remains the key rerating event [#10-K-2026-03-17]High impact
For a low-coverage, single-asset retina biotech, the first-half-2027 preliminary-data window for TH103 is the main binary inflection. Positive data could support a materially higher valuation, while any efficacy, safety, or dosing miss would likely reset expectations.
2027-10-01catalystRunway into Q4 2027 reduces near-term dilution pressure but does not eliminate financing risk [#10-Q-2026-05-12][#10-K-2026-03-17]High impact
The filings point to funding that extends into late 2027, which lowers immediate capital-markets pressure and buys time for TH103 data generation. Even so, this is still a small biotech with one core program, so burn acceleration or a setback in development could bring financing risk back quickly.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-27 • Updated nightlySource: Internal modelMethodology